Abbvie Inc (NYSE: ABBV) has a price-to-earnings ratio that is above its average at 90.75x. The stock has a 36-month beta value of 0.54. Opinions on the stock are mixed, with 11 analysts rating it as a “buy,” 6 as “overweight,” 10 as “hold,” and 0 as “sell.”
The public float for ABBV is 1.76B, and at present, short sellers hold a 1.11% of that float. On March 10, 2025, the average trading volume of ABBV was 6.07M shares.
ABBV) stock’s latest price update
Abbvie Inc (NYSE: ABBV)’s stock price has soared by 1.28 in relation to previous closing price of 214.29. Nevertheless, the company has seen a gain of 2.62% in its stock price over the last five trading days. fool.com reported 2025-03-10 that It’s not too often that pharmaceutical drugs become household names, but that’s happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound — the leading anti-obesity therapies — are now well known and are generating billions of dollars in annual sales.
ABBV’s Market Performance
Abbvie Inc (ABBV) has seen a 2.62% rise in stock performance for the week, with a 12.47% gain in the past month and a 22.99% surge in the past quarter. The volatility ratio for the week is 2.60%, and the volatility levels for the past 30 days are at 2.07% for ABBV. The simple moving average for the past 20 days is 7.01% for ABBV’s stock, with a 18.26% simple moving average for the past 200 days.
Analysts’ Opinion of ABBV
Many brokerage firms have already submitted their reports for ABBV stocks, with BofA Securities repeating the rating for ABBV by listing it as a “Neutral.” The predicted price for ABBV in the upcoming period, according to BofA Securities is $191 based on the research report published on December 10, 2024 of the previous year 2024.
Daiwa Securities, on the other hand, stated in their research note that they expect to see ABBV reach a price target of $180. The rating they have provided for ABBV stocks is “Neutral” according to the report published on December 05th, 2024.
Leerink Partners gave a rating of “Outperform” to ABBV, setting the target price at $206 in the report published on November 22nd of the previous year.
ABBV Trading at 15.26% from the 50-Day Moving Average
After a stumble in the market that brought ABBV to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.64% of gains for the given period.
Volatility was left at 2.07%, however, over the last 30 days, the volatility rate increased by 2.60%, as shares surge +14.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.00% upper at present.
During the last 5 trading sessions, ABBV rose by +2.91%, which changed the moving average for the period of 200-days by +32.26% in comparison to the 20-day moving average, which settled at $202.84. In addition, Abbvie Inc saw 22.13% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABBV starting from GONZALEZ RICHARD A, who sale 92,460 shares at the price of $205.11 back on Feb 28 ’25. After this action, GONZALEZ RICHARD A now owns 395,097 shares of Abbvie Inc, valued at $18,964,471 using the latest closing price.
GONZALEZ RICHARD A, the Director of Abbvie Inc, sale 6,168 shares at $210.53 during a trade that took place back on Mar 03 ’25, which means that GONZALEZ RICHARD A is holding 388,929 shares at $1,298,549 based on the most recent closing price.
Stock Fundamentals for ABBV
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.74 for the gross margin
The net margin for Abbvie Inc stands at 0.08. The total capital return value is set at 0.09. Equity return is now at value 61.94, with 3.14 for asset returns.
Based on Abbvie Inc (ABBV), the company’s capital structure generated 0.95 points at debt to capital in total, while cash flow to debt ratio is standing at 0.28. The debt to equity ratio resting at 20.19. The interest coverage ratio of the stock is 3.41.
Currently, EBITDA for the company is 14.91 billion with net debt to EBITDA at 3.39. When we switch over and look at the enterprise to sales, we see a ratio of 7.88. The receivables turnover for the company is 5.16for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.66.
Conclusion
To sum up, Abbvie Inc (ABBV) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
